Wall Street analysts expect that Tandem Diabetes Care, Inc. (NASDAQ:TNDM) will announce ($3.87) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Tandem Diabetes Care’s earnings. The highest EPS estimate is ($3.30) and the lowest is ($4.20). Tandem Diabetes Care reported earnings per share of ($0.97) during the same quarter last year, which would indicate a negative year over year growth rate of 299%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 7th.

On average, analysts expect that Tandem Diabetes Care will report full-year earnings of ($17.90) per share for the current fiscal year, with EPS estimates ranging from ($18.90) to ($15.80). For the next fiscal year, analysts forecast that the firm will report earnings of ($10.53) per share, with EPS estimates ranging from ($13.10) to ($7.20). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, July 27th. The medical device company reported ($4.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($4.80) by $0.40. The business had revenue of $21.30 million for the quarter, compared to analyst estimates of $21.74 million. Tandem Diabetes Care had a negative net margin of 110.70% and a negative return on equity of 1,177.11%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter last year, the business posted ($6.00) EPS.

Several equities analysts recently commented on TNDM shares. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $15.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective (down previously from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Tandem Diabetes Care has an average rating of “Buy” and a consensus price target of $29.31.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Tandem Diabetes Care by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after buying an additional 32,991 shares in the last quarter. Keybank National Association OH grew its stake in Tandem Diabetes Care by 32.7% in the 2nd quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after buying an additional 72,177 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Tandem Diabetes Care by 93.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after buying an additional 280,551 shares in the last quarter. Iguana Healthcare Management LLC grew its stake in Tandem Diabetes Care by 33.3% in the 1st quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after buying an additional 25,000 shares in the last quarter. Finally, Paulson & CO. Inc. purchased a new position in Tandem Diabetes Care in the 1st quarter worth approximately $600,000. 36.64% of the stock is owned by institutional investors and hedge funds.

Tandem Diabetes Care (TNDM) traded up 7.26% during mid-day trading on Wednesday, hitting $5.69. 123,524 shares of the company traded hands. The firm has a 50 day moving average of $6.81 and a 200 day moving average of $7.89. Tandem Diabetes Care has a one year low of $3.90 and a one year high of $78.90. The firm’s market capitalization is $28.58 million.

TRADEMARK VIOLATION WARNING: “Tandem Diabetes Care, Inc. (TNDM) Expected to Post Earnings of -$3.87 Per Share” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/11/tandem-diabetes-care-inc-tndm-expected-to-post-earnings-of-3-87-per-share.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.